Pancreatic Lesions in von Hippel-Lindau Disease? A Systematic Review and Meta-synthesis of the Literature

Journal of Gastrointestinal Surgery

Volumn 16, Issue 7, 2012, Pages 1422-1428

  Charlesworth, Michael ^a   Verbeke, Caroline S ^b   Falk, Gavin A ^c   Walsh, Matthew ^c   Smith, Andrew M ^a   Morris Stiff, Gareth ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Pancreas; von Hippel Lindau disease

Indexed keywords

CYSTADENOMA; HUMAN; META ANALYSIS; NEUROENDOCRINE TUMOR; PANCREAS CYST; PANCREAS TUMOR; PREVALENCE; REVIEW; VON HIPPEL LINDAU DISEASE;

CYSTADENOMA, SEROUS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC CYST; PANCREATIC NEOPLASMS; PREVALENCE; VON HIPPEL-LINDAU DISEASE;

EID: 84862819571     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1847-0     Document Type: Review

References (46)

1. Hippel EV. Die anatomische Grundlage der mon vir beschriebenen "sehr seltene Erkrankung der Netzhaut". A von Grafe's Arch Opthalmol. 1911; 79: 350-77.
2. Lindau A. Studien uber kleinhirnzysten: bau, pathogenese and beziehungen zur angiomatosis retinae. Acta Pathol Microbiol Scand Suppl. 1926; 1(suppl. II): 1-128.
3. Melmon KL, Rosen SW. Lindau's Disease. Review of the Literature and Study of a Large Kindred. Am J Med. 1964 Apr; 36: 595-617.
4. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003 Jun 14; 361(9374): 2059-67.
5. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988 Mar 17; 332(6161): 268-9.
6. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993 May 28; 260(5112): 1317-20.
7. Duan DR, Humphrey JS, Chen DY, Weng Y, Sukegawa J, Lee S, et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A. 1995 Jul 3; 92(14): 6459-63.
8. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999 May 20; 399(6733): 271-5.
9. Knudson AG, Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 1985 Apr; 45(4): 1437-43.
10. Richard S, David P, Marsot-Dupuch K, Giraud S, Beroud C, Resche F. Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurg Rev. 2000 Mar; 23(1): 1-22; discussion 3-4.
11. Maher ER, Kaelin WG, Jr. von Hippel-Lindau disease. Medicine (Baltimore). 1997 Nov; 76(6): 381-91.
12. Maddock IR, Moran A, Maher ER, Teare MD, Norman A, Payne SJ, et al. A genetic register for von Hippel-Lindau disease. J Med Genet. 1996 Feb; 33(2): 120-7.
13. Richard S, Campello C, Taillandier L, Parker F, Resche F. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J Intern Med. 1998 Jun; 243(6): 547-53.
14. Lamiell JM, Salazar FG, Hsia YE. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore). 1989 Jan; 68(1): 1-29.
15. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000 Apr 19; 283(15): 2008-12.
16. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007 Jun; 36(3): 666-76.
17. Neumann HP, Dinkel E, Brambs H, Wimmer B, Friedburg H, Volk B, et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology. 1991 Aug; 101(2): 465-71.
18. Hough DM, Stephens DH, Johnson CD, Binkovitz LA. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol. 1994 May; 162(5): 1091-4.
19. Cheng TY, Su CH, Shyr YM, Lui WY. Management of pancreatic lesions in von Hippel-Lindau disease. World J Surg. 1997 Mar-Apr; 21(3): 307-12.
20. Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M, Lubensky I, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery. 1998 Dec; 124(6): 1153-9.
21. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000 Oct; 119(4): 1087-95.
22. Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000 Dec; 128(6): 1022-7; discussion 7-8.
23. Mukhopadhyay B, Sahdev A, Monson JP, Besser GM, Reznek RH, Chew SL. Pancreatic lesions in von Hippel-Lindau disease. Clin Endocrinol (Oxf). 2002 Nov; 57(5): 603-8.
24. Delman KA, Shapiro SE, Jonasch EW, Lee JE, Curley SA, Evans DB, et al. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg. 2006 May; 30(5): 665-9.
25. Yamasaki I, Nishimori I, Ashida S, Kohsaki T, Onishi S, Shuin T. Clinical characteristics of pancreatic neuroendocrine tumors in Japanese patients with von Hippel-Lindau disease. Pancreas. 2006 Nov; 33(4): 382-5.
26. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007 Dec; 142(6): 814-8; discussion 8 e1-2.
27. Lee KH, Lee JS, Kim BJ, Lee JK, Kim SH, Lee KT. Pancreatic involvement in Korean patients with von Hippel-Lindau disease. J Gastroenterol. 2009; 44(5): 447-52.
28. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi: 10. 1371/journal. pmed1000097.
29. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003 Jan; 98(1): 82-94.
30. Filling-Katz MR, Choyke PL, Oldfield E, Charnas L, Patronas NJ, Glenn GM, et al. Central nervous system involvement in Von Hippel-Lindau disease. Neurology. 1991 Jan; 41(1): 41-6.
31. Horton WA, Wong V, Eldridge R. Von Hippel-Lindau disease: clinical and pathological manifestations in nine families with 50 affected members. Arch Intern Med. 1976 Jul; 136(7): 769-77.
32. Mohr VH, Vortmeyer AO, Zhuang Z, Libutti SK, Walther MM, Choyke PL, et al. Histopathology and molecular genetics of multiple cysts and microcystic (serous) adenomas of the pancreas in von Hippel-Lindau patients. Am J Pathol. 2000 Nov; 157(5): 1615-21.
33. Kaelin WG, Jr. Cancer. Many vessels, faulty gene. Nature. 1999 May 20; 399(6733): 203-4.
34. Safo AO, Pambuccian SE. Pancreatic manifestations of von Hippel-Lindau disease. Arch Pathol Lab Med. 2010 Jul; 134(7): 1080-3.
35. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008 Oct 1; 113(7 Suppl): 1807-43.
36. Pawlu C, Bausch B, Reisch N, Neumann HP. Genetic testing for pheochromocytoma-associated syndromes. Ann Endocrinol (Paris). 2005 Jun; 66(3): 178-85.
37. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am. 2007 Jun; 21(3): 575-81; x.
38. Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007 Mar; 21(1): 163-72.
39. Walther MM, Choyke PL, Glenn G, Lyne JC, Rayford W, Venzon D, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999 May; 161(5): 1475-9.
40. Grubb RL, 3rd, Choyke PL, Pinto PA, Linehan WM, Walther MM. Management of von Hippel-Lindau-associated kidney cancer. Nat Clin Pract Urol. 2005 May; 2(5): 248-55.
41. Roland CF, van Heerden JA. Nonpancreatic primary tumors with metastasis to the pancreas. Surg Gynecol Obstet. 1989 Apr; 168(4): 345-7.
42. Minni F, Casadei R, Perenze B, Greco VM, Marrano N, Margiotta A, et al. Pancreatic metastases: observations of three cases and review of the literature. Pancreatology. 2004; 4(6): 509-20.
43. Kogire M, Hosotani R, Kondo M, Itoh K, Doi R, Terachi T, et al. Pancreatic lesions in von Hippel-Lindau syndrome: the coexistence of metastatic tumors from renal cell carcinoma and multiple cysts. Surg Today. 2000; 30(4): 380-2.
44. Chambers TP, Fishman EK, Hruban RH. Pancreatic metastases from renal cell carcinoma in von Hippel-Lindau disease. Clin Imaging. 1997 Jan-Feb; 21(1): 40-2.
45. Sugiyama M, Katsura M, Yamamoto K, Nouchi W, Abe N, Hatano N, et al. Pancreatic metastasis from renal cell carcinoma causing massive gastrointestinal bleeding in von Hippel-Lindau disease. Hepatogastroenterology. 1999 Mar-Apr; 46(26): 1199-201.
46. Maeda H, Okabayashi T, Kobayashi M, Araki K, Kohsaki T, Nishimori I, et al. Emergency pancreatoduodenectomy for pancreatic metastasis from renal cell carcinoma in a patient with von Hippel-Lindau disease: a case report. Dig Dis Sci. 2006 Aug; 51(8): 1383-7.